Acknowledgements
The authors thank Sanofi-Aventis R&D for providing access to the complete trial database from the satavaptan phase III trials in cirrhotic ascites and for permission to perform the analyses included in this publication.
Disclosure statement
No potential conflict of interest was reported by the authors.